Lamictal ODT (Lamotrigine) Patent Expiration, LOE Window & CMS Spending
Lamictal ODT (Lamotrigine) by GSK: Off-Patent Genericized (AB Competition), 8 AB generics, $8.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N022251 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $8.8M |
| 2024 Medicare Part D Spend | $3.0M |
| 2024 Medicaid Spend | $5.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.